Reata Pharmaceuticals, Inc. (RETA)
| Market Cap | 4.09B |
| Revenue (ttm) | 8.50M |
| Net Income (ttm) | -368.92M |
| Shares Out | 33.71M |
| EPS (ttm) | -11.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $116.99 |
| Previous Close | $117.15 |
| Change ($) | -0.16 |
| Change (%) | -0.14% |
| Day's Open | 118.81 |
| Day's Range | 115.88 - 118.81 |
| Day's Volume | 243,035 |
| 52-Week Range | 93.53 - 247.74 |
New York, New York--(Newsfile Corp. - December 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...
NEW YORK, Dec. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in th...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwee...
Los Angeles, California--(Newsfile Corp. - December 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata...
New York, New York--(Newsfile Corp. - December 10, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA...
Los Angeles, California--(Newsfile Corp. - December 10, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reat...
LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--DEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc.
New York, New York--(Newsfile Corp. - December 9, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities ...
Los Angeles, California--(Newsfile Corp. - December 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata ...
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the ...
NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (...
Los Angeles, California--(Newsfile Corp. - December 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata ...
New York, New York--(Newsfile Corp. - December 7, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...
Los Angeles, California--(Newsfile Corp. - December 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata...
PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing o...
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwee...
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has p...
PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the launch of...
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that h...
New York, New York--(Newsfile Corp. - November 29, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA...
NEW YORK, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Reata Pharmaceuticals, Inc. (...
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action t...
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) and...
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.
New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...
PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that t...
New York, New York--(Newsfile Corp. - November 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA)...
Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata...
NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15...
New York, New York--(Newsfile Corp. - November 13, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA...
New York, New York--(Newsfile Corp. - November 11, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities...
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q3 2020 Results - Earnings Call Transcript
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel ...
Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.
BARDOXOLONE ACHIEVED THE YEAR 2 PRIMARY AND KEY SECONDARY ENDPOINT S WITH STATISTICALLY SIGNIFICANT IMPROVEMENT S IN EGFR AS COMPARED TO PLACEBO AT WEEK 100 AND WEEK 104
REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15,...
PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that i...
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and cer...
New York, New York--(Newsfile Corp. - October 30, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. (...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and Au...
PLANO, Texas, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that r...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and Au...
NEW YORK, Oct. 23, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pha...
New York, New York--(Newsfile Corp. - October 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secur...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASD...
New York, New York--(Newsfile Corp. - October 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Reata Pharmaceuticals, Inc. (NA...
Smaller biotechs would make nice additions to pharma companies in similar areas of therapy
New York, New York--(Newsfile Corp. - October 21, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the secur...
About RETA
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone th... [Read more...]
| Industry Biotechnology | IPO Date May 26, 2016 |
| CEO J. Warren Huff | Employees 220 |
| Stock Exchange NASDAQ | Ticker Symbol RETA |
Financial Performance
In 2019, RETA's revenue was $26.52 million, a decrease of -50.52% compared to the previous year's $53.59 million. Losses were -$290.17 million, 260.3% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for RETA stock is "Strong Buy." The 12-month stock price forecast is 246.75, which is an increase of 110.92% from the latest price.